Replies to post #220536 on Biotech Values

[faxedreceipts]

Good point. Thanks for your perspective.

[Whalatane]

Dew ..ESPR / MDGL etc
I'm on a PCSK9 plus Zetia ...cost thru Kaiser is around $280 a month
I'll get a lipid panel run at the end of the month and if I remember will post the results .
My LDL cholesterol without drug therapy is around 300 mg/dl. I'm hetero FH

Max dose Crestor ( the strongest Statin ) , plus Zetia gets my LDL down to 120-140mg/dl .
I want to get my LDL below 70mg/dl so we'll see if the PCSK9 / Zetia combo can do that .

The problem I see for ESPR. ( beside price competition ) is
1 ) roughly 1% of those in their trials experience elevations in ALT / AST ( Liver enzymes ) greater then 3 times normal limit
2) MDGL . MGL-3196 lowers LDL cholesterol slightly better then ESPR drug in a similar population ...28.5 % LDL reduction vs 28% LDL reduction .
While ESPR's drug significantly lower hs Crp , MGL-3196 significantly lower risk markers such as ApoB, Lp9a ) and TG's
BUT ...most of all MGL-3196 reduces Liver enzymes with more normalization of ALT

So here we have a drug MGL-3196 that lowers CV risk markers ( LDL etc ) AND improves Liver function , reduces Liver fat and to some extent , may reverse Liver fibrosis .

Seems to me a far better drug then ESPR's.

Comments , counter arguments welcome.

Believe MDGL is releasing updated Lipid data at a conference this wk . Anyone have any info on that ?

Kiwi

[DewDiligence]

AMGN cuts Repatha’s US list price 60%—to $5,850/yr—inline with actual post-rebate price:

https://finance.yahoo.com/news/amgen-cuts-price-cholesterol-drug-202946728.html

For patients getting Repatha through Medicare Part D (or Medicare Advantage with a Part-D component), a fixed copay amount will replace the standard coinsurance calculated as a percentage of the list price, saving these patients a considerable sum—see slide #8 below.


CC slides:
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NzAwODczfENoaWxkSUQ9NDEyNDY0fFR5cGU9MQ==&t=1

[DewDiligence]

ESPR—Daiichi grabs European commercial rights for bempedoic acid:

https://investor.esperion.com/news-releases/news-release-details/esperion-announces-agreement-daiichi-sankyo-europe-dse

Under the terms of the licensing agreement, Esperion will grant Daiichi Sankyo Europe exclusive commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination pill in the European Economic Area and Switzerland. Daiichi Sankyo Europe will be responsible for commercialization in the territories.

Esperion will receive an upfront cash payment of $150 million as well as $150 million upon first commercial sales in the territory. Esperion is also eligible to receive a substantial additional regulatory milestone payment upon the grant of the Marketing Authorization in the EU for the CV Risk Reduction Label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, Esperion is eligible to receive additional sales milestone payments. Finally, Esperion will receive substantial tiered royalties on net territory sales.

ESPR is up only slightly in PM trading.